BU-NOT-SET

CONTACT US
Recipharm’s global teams support and engage with their local communities in the fight against COVID-19
  • Corporate
Eyes
Insight
Recipharm launches new virtual inspection and audit tool for customers, in light of COVID-19 outbreak
  • Manufacturing
Eyes
Insight
Recipharm 25 years
  • Corporate
24 years
Brochure
API range
  • Drug substance
white pills
Fact sheet
Inhibition of 19S proteasome deubiquitinating activity in Schistosoma mansoni affects viability, oviposition, and structural changes
  • Drug substance
Eyes
Insight
The demand for antibiotics and its impact on the pharmaceutical industry since the outbreak of COVID-19
  • Industry trends
Eyes
Insight
Women in leadership
  • Corporate
Eyes
Insight
The state of the oral solid dose development and manufacturing market
  • Drug product
Eyes
Insight
Characterising APIs is Essential for Combo Drug Formulations
  • Drug substance
Eyes
Insight
Case study
  • Drug product
  • Manufacturing
Science-led OSD reformulation
Case study
  • Development
  • Drug product
De-risking complex generic OSD development
Insight
  • Development
  • Drug product
Science-led OSD development
White paper
  • Drug product
  • Manufacturing
Advanced deformulation for complex generic development
Webinar
  • Development
  • Drug product
How to turn development challenges into predictable outcomes
Insight
  • Drug product
Managing risk as high-potency manufacturing scales
Insight
  • Drug product
Safely scaling high potency API manufacturing
eBook
  • Development
  • Drug product
A predictive approach to complex OSD development
Video
  • Development
Predictable development for uneventful manufacturing